Advanced search
1 file | 136.08 KB Add to list

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

(2011) SUPPORTIVE CARE IN CANCER. 19(11). p.1753-1760
Author
Organization
Abstract
The aim of this study was to determine the smallest changes in health-related quality of life (HRQOL) scores in a subset of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) scales, which could be considered as clinically meaningful in patients with non-small-cell lung cancer (NSCLC). WHO performance status (PS) and weight change were used as clinical anchors to determine minimal important differences (MIDs) in HRQOL change scores (range, 0-100) in the EORTC QLQ-C30 scales. Selected distribution-based methods were used for comparison. In a pooled dataset of 812 NSCLC patients undergoing treatment, the values determined to represent the MID depended on whether patients were improving or deteriorating. MID estimates for improvement (based on a one-category change in PS, 5 -aEuro parts per thousand < 20% weight gain) were physical functioning (9, 5); role functioning (14, 7); social functioning (5, 7); global health status (9, 4); fatigue (14, 5); and pain (16, 2). The respective MID estimates for deterioration (based on PS, weight loss) were physical (4, 6); role (5, 5); social (7, 9); global health status (4, 4); fatigue (6, 11); and pain (3, 7). Based on the selected QLQ-C30 scales, the MID may depend upon whether the patients' PS is improving or worsening, but our results are not definitive. The MID estimates for the specified scales can help clinicians and researchers evaluate the significance of changes in HRQOL and assess the value of a health care intervention or compare treatments. The estimates also can be useful in determining sample sizes in the design of future clinical trials.
Keywords
EUROPEAN-ORGANIZATION, CLINICALLY IMPORTANT DIFFERENCES, MEANINGFUL CHANGE, FUNCTIONAL ASSESSMENT, STANDARD-DEVIATION, REPORTED OUTCOMES, QUESTIONNAIRE, UNIVERSALITY, CISPLATIN, HALF, Minimal important difference, Health-related quality of life, EORTC QLQ-C30, Anchoring

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 136.08 KB

Citation

Please use this url to cite or link to this publication:

MLA
Maringwa, John T, Chantal Quinten, Madeleine King, et al. “Minimal Important Differences for Interpreting Health-related Quality of Life Scores from the EORTC QLQ-C30 in Lung Cancer Patients Participating in Randomized Controlled Trials.” SUPPORTIVE CARE IN CANCER 19.11 (2011): 1753–1760. Print.
APA
Maringwa, J. T., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., et al. (2011). Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. SUPPORTIVE CARE IN CANCER, 19(11), 1753–1760.
Chicago author-date
Maringwa, John T, Chantal Quinten, Madeleine King, Jolie Ringash, David Osoba, Corneel Coens, Francesca Martinelli, et al. 2011. “Minimal Important Differences for Interpreting Health-related Quality of Life Scores from the EORTC QLQ-C30 in Lung Cancer Patients Participating in Randomized Controlled Trials.” Supportive Care in Cancer 19 (11): 1753–1760.
Chicago author-date (all authors)
Maringwa, John T, Chantal Quinten, Madeleine King, Jolie Ringash, David Osoba, Corneel Coens, Francesca Martinelli, Jurgen Vercauteren, Charles S Cleeland, Henning Flechtner, Carolyn Gotay, Eva Greimel, Martin J Taphoorn, Bryce B Reeve, Joseph Schmucker-Von Koch, Joachim Weis, Egbert F Smit, Jan Van Meerbeeck, and Andrew Bottomley. 2011. “Minimal Important Differences for Interpreting Health-related Quality of Life Scores from the EORTC QLQ-C30 in Lung Cancer Patients Participating in Randomized Controlled Trials.” Supportive Care in Cancer 19 (11): 1753–1760.
Vancouver
1.
Maringwa JT, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. SUPPORTIVE CARE IN CANCER. 2011;19(11):1753–60.
IEEE
[1]
J. T. Maringwa et al., “Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials,” SUPPORTIVE CARE IN CANCER, vol. 19, no. 11, pp. 1753–1760, 2011.
@article{2046568,
  abstract     = {{The aim of this study was to determine the smallest changes in health-related quality of life (HRQOL) scores in a subset of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) scales, which could be considered as clinically meaningful in patients with non-small-cell lung cancer (NSCLC).
WHO performance status (PS) and weight change were used as clinical anchors to determine minimal important differences (MIDs) in HRQOL change scores (range, 0-100) in the EORTC QLQ-C30 scales. Selected distribution-based methods were used for comparison.
In a pooled dataset of 812 NSCLC patients undergoing treatment, the values determined to represent the MID depended on whether patients were improving or deteriorating. MID estimates for improvement (based on a one-category change in PS, 5 -aEuro parts per thousand < 20% weight gain) were physical functioning (9, 5); role functioning (14, 7); social functioning (5, 7); global health status (9, 4); fatigue (14, 5); and pain (16, 2). The respective MID estimates for deterioration (based on PS, weight loss) were physical (4, 6); role (5, 5); social (7, 9); global health status (4, 4); fatigue (6, 11); and pain (3, 7).
Based on the selected QLQ-C30 scales, the MID may depend upon whether the patients' PS is improving or worsening, but our results are not definitive. The MID estimates for the specified scales can help clinicians and researchers evaluate the significance of changes in HRQOL and assess the value of a health care intervention or compare treatments. The estimates also can be useful in determining sample sizes in the design of future clinical trials.}},
  author       = {{Maringwa, John T and Quinten, Chantal and King, Madeleine and Ringash, Jolie and Osoba, David and Coens, Corneel and Martinelli, Francesca and Vercauteren, Jurgen and Cleeland, Charles S and Flechtner, Henning and Gotay, Carolyn and Greimel, Eva and Taphoorn, Martin J and Reeve, Bryce B and Schmucker-Von Koch, Joseph and Weis, Joachim and Smit, Egbert F and Van Meerbeeck, Jan and Bottomley, Andrew}},
  issn         = {{0941-4355}},
  journal      = {{SUPPORTIVE CARE IN CANCER}},
  keywords     = {{EUROPEAN-ORGANIZATION,CLINICALLY IMPORTANT DIFFERENCES,MEANINGFUL CHANGE,FUNCTIONAL ASSESSMENT,STANDARD-DEVIATION,REPORTED OUTCOMES,QUESTIONNAIRE,UNIVERSALITY,CISPLATIN,HALF,Minimal important difference,Health-related quality of life,EORTC QLQ-C30,Anchoring}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{1753--1760}},
  title        = {{Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials}},
  url          = {{http://dx.doi.org/10.1007/s00520-010-1016-5}},
  volume       = {{19}},
  year         = {{2011}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: